Abstract

Neurodegenerative diseases originate from neuronal loss in the central nervous system (CNS). These debilitating diseases progress with age and have become common due to an increase in longevity. The National Institute of Environmental Health Science’s 2021 annual report suggests around 6.2 million Americans are living with Alzheimer’s disease, and there is a possibility that there will be 1.2 million Parkinson’s disease patients in the USA by 2030. There is no clear-cut universal mechanism for identifying neurodegenerative diseases, and therefore, they pose a challenge for neurobiology scientists. Genetic and environmental factors modulate these diseases leading to familial or sporadic forms. Prior studies have shown that miRNA levels are altered during the course of the disease, thereby suggesting that these noncoding RNAs may be the contributing factor in neurodegeneration. In this review, we highlight the role of miRNAs in the pathogenesis of neurodegenerative diseases. Through this review, we aim to achieve four main objectives: First, we highlight how dysregulation of miRNA biogenesis led to these diseases. Second, we highlight the computational or bioinformatics tools required to identify the putative molecular targets of miRNAs, leading to biological molecular pathways or mechanisms involved in these diseases. Third, we focus on the dysregulation of miRNAs and their target genes leading to several neurodegenerative diseases. In the final section, we highlight the use of miRNAs as potential diagnostic biomarkers in the early asymptomatic preclinical diagnosis of these age-dependent debilitating diseases. Additionally, we discuss the challenges and advances in the development of miRNA therapeutics for brain targeting. We list some of the innovative strategies employed to deliver miRNA into target cells and the relevance of these viral and non-viral carrier systems in RNA therapy for neurodegenerative diseases. In summary, this review highlights the relevance of studying brain-enriched miRNAs, the mechanisms underlying their regulation of target gene expression, their dysregulation leading to progressive neurodegeneration, and their potential for biomarker marker and therapeutic intervention. This review thereby highlights ways for the effective diagnosis and prevention of these neurodegenerative disorders in the near future.

Highlights

  • Noncoding RNAs comprise 95% of human cellular RNAs [2]. These noncoding RNAs participate in translational regulation and have thereby led researchers to seek an in-depth understanding of mRNA translation [3]. miRNAs are small, noncoding

  • The last decade has seen an increase in the number of groups using in vitro and in vivo models to understand the roles of brain-enriched miRNAs in human neurodegenerative diseases

  • This paper has provided a comprehensive review of this field, but it is hoped that by highlighting key papers, this review may inspire those new to this area to begin asking new questions and making advancements in the field of miRNAs’ role in causing neurodegeneration and its use in designing effective diagnostics and therapeutic tools

Read more

Summary

Introduction

The way the inhibition of producing proteins is achieved is dependent on how well the base pairs bind together (complementarity), which in turn activates one of two mechanisms-degradation of the mRNA or the blockage of translation These small but impactful molecules make up at least 1% of the human genome, and the dysfunctional manner of miRNAs has been closely associated with many known diseases. Dysregulation in Dicer, Drosha, and RISC complexes leads to disruption of miRNA biogenesis, defective cellular processes, and the onset of neuronal degeneration. In HD the mutant Htt (Huntington) gene inhibits the formation of p-bodies (processing bodies) by interacting with Ago and Ago, which are involved in miRNA biogenesis [29] This hints toward a possibility of miRNA dysregulation in the brains of HD patients

Tools for Detecting miRNA Targets
Schematic
Findings
Conclusions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call